Healthcare Aug 23, 2021 07:42 AM (GMT+8) · EqualOcean
Financial Associated Press, August 23 - Baiji Shenzhou announced that the drug evaluation center (CDE) of China's State Drug Administration (nmpa) has accepted its anti-PD-1 antibody drug baizean ®( Tirelizumab injection) combined with chemotherapy is a new indication for first-line treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).
Related companies: